ImmunityBio

system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman. Since then we have progressed into a late-stage clinical company with more than 40 Phase I, II, or III clinical trials (company-sponsored and investigator-initiated) in development across 19 indications in solid and liquid cancers and infectious diseases. Our proprietary natural killer cell platform can be easily expanded, genetically modified, and cryopreserved and offers multiple modes of cytotoxicity. Our lead antibody cytokine fusion protein, Anktiva, has received FDA Breakthrough Therapy designation for one of the most common and difficult to treat types of bladder cancer (BCG-unresponsive non-muscle invasive bladder cancer). Our work is led by a senior team with highly complementary and broad expertise across novel scientific areas including genomics and proteomics, monoclonal antibodies, fusion proteins, vaccines, and autologous and allogeneic cell therapy, based on experiences at companies ranging from biotech startups to large commercial pharmaceutical enterprises.